For the quarter ending 2026-04-03, EXEL had -$256,336K decrease in cash & cash equivalents over the period. $250,336K in free cash flow.
| Cash Flow | 2026-04-03 | 2026-01-02 | 2025-10-03 | 2025-07-04 |
|---|---|---|---|---|
| Revenues | 610,812 | 598,663 | 597,755 | - |
| Cost of goods sold | 19,953 | 26,481 | 18,574 | - |
| Drug discovery | 19,476 | 26,483 | 23,838 | - |
| Development | 135,715 | 146,822 | 133,645 | - |
| Selling, general, and administrative | 122,870 | 109,701 | 103,129 | - |
| Other segment items | 61,238 | 53,914 | 82,078 | - |
| Interest income | 16,127 | 17,426 | 15,922 | - |
| Provision for income taxes | 57,220 | 8,160 | 58,835 | - |
| Net income | 210,467 | 244,528 | 193,578 | 184,848 |
| Depreciation and amortization | 6,948 | 6,946 | 7,422 | 7,342 |
| Impairment of long-lived assets | - | 0 | 0 | - |
| Stock-based compensation | 29,050 | 20,097 | 30,885 | 36,071 |
| Non-cash lease expense | 5,994 | 6,019 | 6,044 | 6,070 |
| Deferred taxes | - | -126,237 | - | - |
| Acquired in-process research and development technology | 2,025 | 5,000 | 6,249 | 750 |
| Other, net | 2,019 | 2,348 | -1,356 | 5,831 |
| Trade receivables, net | 42,031 | -22,809 | 17,370 | 10,718 |
| Inventory | 3,389 | -13,806 | 4,149 | -2,639 |
| Prepaid expenses and other assets | -58,653 | 97,034 | -47,649 | 104,706 |
| Accrued collaboration liabilities | 4,044 | 355 | 903 | -3,964 |
| Accounts payable and other liabilities | -17,897 | -12,900 | 17,755 | -63,508 |
| Net cash provided by operating activities | 251,845 | 333,515 | 290,322 | 48,993 |
| Purchases of marketable securities | 274,161 | 154,941 | 189,370 | 101,485 |
| Proceeds from maturities and sales of marketable securities | 225,125 | 189,339 | 221,506 | 353,104 |
| Purchases of property, equipment and other, net | 1,509 | 1,157 | 1,482 | 2,838 |
| Acquired in-process research and development technology | 525 | 6,000 | 5,249 | 750 |
| Net cash provided by (used in) investing activities | -51,070 | 27,241 | 25,405 | 248,031 |
| Payments for repurchases of common stock | 430,352 | 257,618 | 104,035 | 301,924 |
| Proceeds from issuance of common stock under the equity incentive plan | 7,472 | 7,875 | 3,552 | 26,083 |
| Taxes paid related to net share settlement of equity awards | 34,231 | 4,825 | 3,377 | 40,502 |
| Net cash used in financing activities | -457,111 | -254,568 | -103,860 | -316,343 |
| Net decrease in cash and cash equivalents | -256,336 | 106,188 | 211,867 | -19,319 |
| Cash and cash equivalents at beginning of period | 482,488 | 376,300 | 217,374 | - |
| Cash and cash equivalents at end of period | 226,152 | 482,488 | 376,300 | - |
EXELIXIS, INC. (EXEL)
EXELIXIS, INC. (EXEL)